|
|
| Line 1: |
Line 1: |
| [[Image:2gfs.gif|left|200px]] | | {{Seed}} |
| | [[Image:2gfs.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
| Line 9: |
Line 10: |
| {{STRUCTURE_2gfs| PDB=2gfs | SCENE= }} | | {{STRUCTURE_2gfs| PDB=2gfs | SCENE= }} |
|
| |
|
| '''P38 Kinase Crystal Structure in complex with RO3201195'''
| | ===P38 Kinase Crystal Structure in complex with RO3201195=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| A novel class of highly selective inhibitors of p38 MAP kinase was discovered from high throughput screening. The synthesis and optimization of a series of 5-amino-N-phenyl-1H-pyrazol-4-yl-3-phenylmethanones is described. An X-ray crystal structure of this series bound in the ATP binding pocket of unphosphorylated p38alpha established the presence of a unique hydrogen bond between the exocyclic amine of the inhibitor and threonine 106 which likely contributes to the selectivity for p38. The crystallographic information was used to optimize the potency and physicochemical properties of the series. The incorporation of the 2,3-dihydroxypropoxy moiety on the pyrazole scaffold resulted in a compound with excellent drug-like properties including high oral bioavailability. These efforts identified 63 (RO3201195) as an orally bioavailable and highly selective inhibitor of p38 which was selected for advancement into Phase I clinical trials.
| | The line below this paragraph, {{ABSTRACT_PUBMED_16509574}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 16509574 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_16509574}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
| Line 29: |
Line 33: |
| [[Category: P38]] | | [[Category: P38]] |
| [[Category: Serine/threonine kinase]] | | [[Category: Serine/threonine kinase]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 05:03:28 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 04:09:52 2008'' |